Clinical Trials

Alzheimer’s Disease & Agitation Phase IIa

A Phase IIa study evaluating SCI-110 in patients with Alzheimer's disease-related agitation, conducted at the Sophie & Abraham Stuchynski Israeli Alzheimer's Medical Center.

Trial outcome

Positive

primary & secondary

Positive results meeting primary and secondary endpoints.

Safety

100%

safe

SCI-110 was found to be safe at all tested doses.

Reduced need for medication

75%

Positive results

Treatment was also found to reduce agitation: 75% of patients did not need additional medication to control agitation, and 75% of patients experienced increased appetite.

Trial site

Sophie & Abraham Stuchynski Israeli Alzheimer’s Medical Center, Israel.

Study population and dose

Patients treated

20 patients were treated with SCI-110 at a daily dose of up to 12.5 mg THC + 800 mg PEA.